Pharma Whistleblower

SAN FRANCISCO – The Ninth Circuit on Thursday revived part of a man’s whistleblower claims against three pharmaceutical companies that he said promoted dangerous off-label uses of the heart drug Integrilin, so the trial court can determine if the whistleblower is an “original source” of the information.

Exit mobile version